Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer (PFE 0.77%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade. Here's why they chose Abbott Laboratories ( ABT -1.00%), AbbVie ( ABBV 2.86%), ...

The stock exceeded the S&P 500 ... The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its ...

In this note, we discuss Pfizer’s stock performance, key takeaways from its recent results, and valuation. PFE stock has seen a decline of 15% from levels of $35 in early January 2021 to around ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...